These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 17935281)

  • 1. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
    Acres B
    J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
    Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
    J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technology evaluation: TG-1031, Transgene SA.
    Doehn C; Jocham D
    Curr Opin Mol Ther; 2000 Feb; 2(1):106-11. PubMed ID: 11249647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
    Ramlau R; Quoix E; Rolski J; Pless M; Lena H; Lévy E; Krzakowski M; Hess D; Tartour E; Chenard MP; Limacher JM; Bizouarne N; Acres B; Halluard C; Velu T
    J Thorac Oncol; 2008 Jul; 3(7):735-44. PubMed ID: 18594319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
    Yuan S; Shi C; Liu L; Han W
    Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
    Dreicer R; Stadler WM; Ahmann FR; Whiteside T; Bizouarne N; Acres B; Limacher JM; Squiban P; Pantuck A
    Invest New Drugs; 2009 Aug; 27(4):379-86. PubMed ID: 18931824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
    Oudard S; Rixe O; Beuselinck B; Linassier C; Banu E; Machiels JP; Baudard M; Ringeisen F; Velu T; Lefrere-Belda MA; Limacher JM; Fridman WH; Azizi M; Acres B; Tartour E
    Cancer Immunol Immunother; 2011 Feb; 60(2):261-71. PubMed ID: 21069322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC1 as a target antigen for cancer immunotherapy.
    Acres B; Limacher JM
    Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
    Sangha R; Butts C
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emepepimut-S for non-small cell lung cancer.
    Corrales-Rodriguez L; Blais N; Soulières D
    Expert Opin Biol Ther; 2011 Aug; 11(8):1091-7. PubMed ID: 21689064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel targeted agents for lung cancer.
    West HJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC1 and breast cancer.
    Apostolopoulos V; Pietersz GA; McKenzie IF
    Curr Opin Mol Ther; 1999 Feb; 1(1):98-103. PubMed ID: 11249691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leuvectin Vical Inc.
    Kaushik A
    Curr Opin Investig Drugs; 2001 Jul; 2(7):976-81. PubMed ID: 11757801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are vaccines making a comeback in non-small-cell lung cancer?
    Nemunaitis JJ
    J Clin Oncol; 2008 Mar; 26(9):1402-3. PubMed ID: 18349390
    [No Abstract]   [Full Text] [Related]  

  • 18. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
    Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
    Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology evaluation: BLP-25, Biomira Inc.
    Morse MA
    Curr Opin Mol Ther; 2001 Feb; 3(1):102-5. PubMed ID: 11249725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5T4 as a target for immunotherapy in renal cell carcinoma.
    Elkord E; Shablak A; Stern PL; Hawkins RE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1705-9. PubMed ID: 19954280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.